<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370028</url>
  </required_header>
  <id_info>
    <org_study_id>DIAMANT</org_study_id>
    <nct_id>NCT04370028</nct_id>
  </id_info>
  <brief_title>Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders</brief_title>
  <acronym>DIAMANT</acronym>
  <official_title>All-Russian Observational Non-interventional Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, prospective, observational, multicenter study. The study enrolls adult&#xD;
      outpatients with CCI from 8 federal districts of the Russian Federation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical data (demographic and clinical characteristics - diagnosis, MoCA test results) are&#xD;
      collected from patients to whom Divaza is prescribed to be taken according to the following&#xD;
      regimen: 2 tablets 3 times per day for 12 weeks.&#xD;
&#xD;
      Neurologists assess the patients' cognitive functions with MoCA scale before starting therapy&#xD;
      with Divaza (visit 1) and 12 weeks after the treatment (visit 2).&#xD;
&#xD;
      The efficacy of Divaza for the treatment of cognitive impairment in patients with chronic&#xD;
      cerebral ischemia (CCI) is evaluated.&#xD;
&#xD;
      Safety is assessed based on the frequency and severity of adverse events. In addition, the&#xD;
      relationship between MoCA test performance and gender or regional social and economic factors&#xD;
      is evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean MoCA Score at Week 1 and the End of the 12-week Therapy</measure>
    <time_frame>week 1 to 12 week</time_frame>
    <description>MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome).MoCA test allows to evaluate the presence of cognitive impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With a MoCA Score &lt;26 at 12 Week</measure>
    <time_frame>12 week</time_frame>
    <description>The number of patients with mild cognitive impairment. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With a MoCA Score ≤ 17 at the End of the 12-week Therapy</measure>
    <time_frame>week1 to week 12</time_frame>
    <description>The number of patients with dementia. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Dynamics of Mean MoCA Score in Each Age Group</measure>
    <time_frame>week1 to week 12</time_frame>
    <description>Age groups:young &lt;35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With a MoCA Score Improvement (Increase in Scores) in Age Groups</measure>
    <time_frame>week1 to week 12</time_frame>
    <description>Age groups:young &lt;35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Relationship Between Cognitive Impairment and Patients' Gender</measure>
    <time_frame>Data measured at baseline</time_frame>
    <description>Evaluation of the relationship between baseline MoCA test results and gender. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>The Relationship Between Cognitive Impairment and Regional Social/Economic Factors</measure>
    <time_frame>Data measured at baseline</time_frame>
    <description>Evaluation of the relationship between baseline MoCA test results and regional developmental social or economic indicators (poverty, infant mortality, migration, life expectancy, innovation rate, professional development, number of university students, number of R&amp;D personnel, resources spent on R&amp;D, number of doctors, number of hospitals and outpatient clinics, hospital capacity, fertility rate, quality of life index,income).&#xD;
Relevance of factors (unitless value) provided. The higher the more influential the factor is.&#xD;
Relevance was assessed with Boruta approach:&#xD;
KURSA, Miron B.; RUDNICKI, Witold R.. Feature Selection with the Boruta Package. Journal of Statistical Software, [S.l.], v. 36, Issue 11, p. 1 - 13, sep. 2010. ISSN 1548-7660. Available at: &lt;http://www.jstatsoft.org/v036/i11&gt;. Date accessed: 24 nov. 2020. doi:http://dx.doi.org/10.18637/jss.v036.i11.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2583</enrollment>
  <condition>Chronic Cerebral Ischemia</condition>
  <arm_group>
    <arm_group_label>Divaza</arm_group_label>
    <description>Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divaza</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Divaza</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult CCI outpatients with cognitive impairment (MoCA score &lt;26) or without one (MoCA score&#xD;
        ≥ 26) recieving unchanged basic therapy of CCI and underlying vascular disease for a 3&#xD;
        month previous to the onset of the study. Diagnosis of сhronic cerebral ischemia (CCI) was&#xD;
        based on the clinical history of underlying vascular disease(atherosclerosis and/or&#xD;
        arterial hypertension) and neurological signs. Vascular nature of cognitive impairment in&#xD;
        patients with MoCA&lt;26 was determined according to NINDS-AIREN criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of either gender aged 18+ years.&#xD;
&#xD;
          2. Diagnosis of chronic cerebral ischemia (CCI) based on the clinical history of&#xD;
             underlying vascular disease(atherosclerosis and/or arterial hypertension) and&#xD;
             neurological signs.&#xD;
&#xD;
          3. Unchanged basic therapy of CCI and underlying vascular disease for a previous 3 month.&#xD;
&#xD;
          4. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other neurological diseases.&#xD;
&#xD;
          2. Any known allergy to/intolerance of any constituent of the medication.&#xD;
&#xD;
          3. Pregnancy, breast-feeding.&#xD;
&#xD;
          4. Participation in other clinical trials for 3 months prior to enrollment in this study.&#xD;
&#xD;
          5. The patient is related to the research personnel of the investigative sites that are&#xD;
             directly involved in the study, or is the immediate relative of the investigator, or&#xD;
             the employee of OOO NPF Materia Medica Holding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <results_first_submitted>December 6, 2020</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2021</results_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: October 2016 January 2017 Location: outpatient clinics from 8 federal districts of the Russian Federation</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Divaza Treatment Group</title>
          <description>All enrolled patients received Divaza 2 tablets 3 times per day for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2583"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1876"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="707"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="695"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety was assessed using the data of all 2583 patients. Within each efficacy and demographic analysis only complete cases approach was used, therefore the number of patients analyzed in efficacy analysis was fewer than 1876</population>
      <group_list>
        <group group_id="B1">
          <title>Divaza Treatment Group</title>
          <description>All participants received Divaza treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1876"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Age was not reported for 23 patients.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1853"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <population>Age was not reported for 23 patients</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Young (&lt;35 yo)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1853"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle aged (35-59 yo)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1853"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elderly (60-75 yo)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1853"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Senile (75-90 yo)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1853"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Within each analysis only complete cases approach was used.Sexual identity of 29 patients was not specified.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1847"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline MoCA score</title>
          <description>MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome).MoCA test allows to evaluate the presence of cognitive impairment</description>
          <population>Baseline MoCA scores were not reported in 21 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1855"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean MoCA Score at Week 1 and the End of the 12-week Therapy</title>
        <description>MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome).MoCA test allows to evaluate the presence of cognitive impairment</description>
        <time_frame>week 1 to 12 week</time_frame>
        <population>MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza Treatment Group</title>
            <description>All analyzed participants received Divaza treatment 2 tablets 3 times per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean MoCA Score at Week 1 and the End of the 12-week Therapy</title>
          <description>MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome).MoCA test allows to evaluate the presence of cognitive impairment</description>
          <population>MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1855"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.42" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired test was performed</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.42</ci_lower_limit>
            <ci_upper_limit>4.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With a MoCA Score &lt;26 at 12 Week</title>
        <description>The number of patients with mild cognitive impairment. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
        <time_frame>12 week</time_frame>
        <population>MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza Treatment Group</title>
            <description>All analyzed participants received Divaza treatment 2 tablets 3 times per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With a MoCA Score &lt;26 at 12 Week</title>
          <description>The number of patients with mild cognitive impairment. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
          <population>MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1855"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Odds ratio of occuring MoCA score &lt;26 was assessed</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.01</ci_lower_limit>
            <ci_upper_limit>8.67</ci_upper_limit>
            <estimate_desc>OR estimated (week 1 to week 12) the higher the better</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With a MoCA Score ≤ 17 at the End of the 12-week Therapy</title>
        <description>The number of patients with dementia. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
        <time_frame>week1 to week 12</time_frame>
        <population>MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza Treatment Group</title>
            <description>All analyzed participants received Divaza treatment 2 tablets 3 times per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With a MoCA Score ≤ 17 at the End of the 12-week Therapy</title>
          <description>The number of patients with dementia. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
          <population>MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1855"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Odds ratio of occuring MoCA score &lt;17 was assessed</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.28</ci_lower_limit>
            <ci_upper_limit>6.64</ci_upper_limit>
            <estimate_desc>OR estimated (week 1 to week 12) the higher the better</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Dynamics of Mean MoCA Score in Each Age Group</title>
        <description>Age groups:young &lt;35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
        <time_frame>week1 to week 12</time_frame>
        <population>Patients who did not reported age or both MoCA scores were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Young Patients&lt;35 yo</title>
            <description>Young Patients&lt;35 yo treated with Divaza</description>
          </group>
          <group group_id="O2">
            <title>Middle-aged Patients 35-59 yo</title>
            <description>Middle-aged patients 35-59 yo treated with Divaza</description>
          </group>
          <group group_id="O3">
            <title>Elderly Patients 60-75 yo</title>
            <description>Elderly patients 60-75 yo treated with Divaza</description>
          </group>
          <group group_id="O4">
            <title>Senile Patients 75-90 yo</title>
            <description>Senile patients 75-90 yo received Divaza</description>
          </group>
        </group_list>
        <measure>
          <title>The Dynamics of Mean MoCA Score in Each Age Group</title>
          <description>Age groups:young &lt;35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
          <population>Patients who did not reported age or both MoCA scores were excluded from analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="1062"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="5.6"/>
                    <measurement group_id="O2" value="20.94" spread="4.93"/>
                    <measurement group_id="O3" value="19.39" spread="4.7"/>
                    <measurement group_id="O4" value="16.23" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="5.6"/>
                    <measurement group_id="O2" value="25.7" spread="3.6"/>
                    <measurement group_id="O3" value="23.9" spread="4.2"/>
                    <measurement group_id="O4" value="20.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change of mean MoCA score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.07</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.375</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change of mean MoCA score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.17</ci_lower_limit>
            <ci_upper_limit>5.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change of mean MoCA score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.16</ci_lower_limit>
            <ci_upper_limit>4.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change of mean MoCA score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>5.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With a MoCA Score Improvement (Increase in Scores) in Age Groups</title>
        <description>Age groups:young &lt;35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
        <time_frame>week1 to week 12</time_frame>
        <population>Patients who did not reported age or both MoCA scores were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Young Patients&lt;35 yo</title>
            <description>Young Patients&lt;35 yo treated with Divaza</description>
          </group>
          <group group_id="O2">
            <title>Middle-aged Patients 35-59 yo</title>
            <description>Middle-aged patients 35-59 yo treated with Divaza</description>
          </group>
          <group group_id="O3">
            <title>Elderly Patients 60-75 yo</title>
            <description>Elderly patients 60-75 yo treated with Divaza</description>
          </group>
          <group group_id="O4">
            <title>Senile Patients 75-90 yo</title>
            <description>Senile patients 75-90 yo received Divaza</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With a MoCA Score Improvement (Increase in Scores) in Age Groups</title>
          <description>Age groups:young &lt;35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
          <population>Patients who did not reported age or both MoCA scores were excluded from analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="1062"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="199"/>
                    <measurement group_id="O3" value="616"/>
                    <measurement group_id="O4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Relationship Between Cognitive Impairment and Patients' Gender</title>
        <description>Evaluation of the relationship between baseline MoCA test results and gender. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
        <time_frame>Data measured at baseline</time_frame>
        <population>Patients who did not reported sex or baseline MoCA score were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Female</title>
            <description>Female patients treated with Divaza</description>
          </group>
          <group group_id="O2">
            <title>Male</title>
            <description>Male patients treated with Divaza</description>
          </group>
        </group_list>
        <measure>
          <title>The Relationship Between Cognitive Impairment and Patients' Gender</title>
          <description>Evaluation of the relationship between baseline MoCA test results and gender. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)</description>
          <population>Patients who did not reported sex or baseline MoCA score were excluded from analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1139"/>
                <count group_id="O2" value="708"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="5.09"/>
                    <measurement group_id="O2" value="18.9" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.803</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.246</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.321</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Relationship Between Cognitive Impairment and Regional Social/Economic Factors</title>
        <description>Evaluation of the relationship between baseline MoCA test results and regional developmental social or economic indicators (poverty, infant mortality, migration, life expectancy, innovation rate, professional development, number of university students, number of R&amp;D personnel, resources spent on R&amp;D, number of doctors, number of hospitals and outpatient clinics, hospital capacity, fertility rate, quality of life index,income).&#xD;
Relevance of factors (unitless value) provided. The higher the more influential the factor is.&#xD;
Relevance was assessed with Boruta approach:&#xD;
KURSA, Miron B.; RUDNICKI, Witold R.. Feature Selection with the Boruta Package. Journal of Statistical Software, [S.l.], v. 36, Issue 11, p. 1 - 13, sep. 2010. ISSN 1548-7660. Available at: &lt;http://www.jstatsoft.org/v036/i11&gt;. Date accessed: 24 nov. 2020. doi:http://dx.doi.org/10.18637/jss.v036.i11.</description>
        <time_frame>Data measured at baseline</time_frame>
        <population>Incomplete data (with respect to used variables) was excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Divaza Treatment Group</title>
            <description>All enrolled patients received Divaza 2 tablets 3 times per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Relationship Between Cognitive Impairment and Regional Social/Economic Factors</title>
          <description>Evaluation of the relationship between baseline MoCA test results and regional developmental social or economic indicators (poverty, infant mortality, migration, life expectancy, innovation rate, professional development, number of university students, number of R&amp;D personnel, resources spent on R&amp;D, number of doctors, number of hospitals and outpatient clinics, hospital capacity, fertility rate, quality of life index,income).&#xD;
Relevance of factors (unitless value) provided. The higher the more influential the factor is.&#xD;
Relevance was assessed with Boruta approach:&#xD;
KURSA, Miron B.; RUDNICKI, Witold R.. Feature Selection with the Boruta Package. Journal of Statistical Software, [S.l.], v. 36, Issue 11, p. 1 - 13, sep. 2010. ISSN 1548-7660. Available at: &lt;http://www.jstatsoft.org/v036/i11&gt;. Date accessed: 24 nov. 2020. doi:http://dx.doi.org/10.18637/jss.v036.i11.</description>
          <population>Incomplete data (with respect to used variables) was excluded</population>
          <units>unitless feature importance</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1797"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.85" lower_limit="39.48" upper_limit="41.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poverty percentage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" lower_limit="7.66" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infant mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.97" lower_limit="7.53" upper_limit="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migration index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" lower_limit="7.23" upper_limit="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life expectancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" lower_limit="5.86" upper_limit="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Professional development index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" lower_limit="5.52" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of R&amp;D personnel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.81" lower_limit="4.7" upper_limit="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitals number</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" lower_limit="5.16" upper_limit="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R&amp;D expenditures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="5" upper_limit="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Innovation rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" lower_limit="5.12" upper_limit="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitals capacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.89" lower_limit="4.46" upper_limit="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fertility rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" lower_limit="4.3" upper_limit="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QoL index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" lower_limit="4.06" upper_limit="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient clinics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" lower_limit="4.32" upper_limit="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nursing personnel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" lower_limit="3.87" upper_limit="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Income level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="3" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>University students</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" lower_limit="3.19" upper_limit="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of doctors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" lower_limit="3.17" upper_limit="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>shadowMax (reference zero-importance feature)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="1.83" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>AEs were collected from all patients received a single dose of Divaza according to patient's complaints and physical examination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Divaza Treatment Group</title>
          <description>All enrolled patients received Divaza 2 tablets 3 times per day for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2583"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2583"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2583"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2583"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2583"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2583"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2583"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2583"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2583"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2583"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2583"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2583"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2583"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikhail Putilovskiy, MD, PhD</name_or_title>
      <organization>OOO NPF Materia Medica Holding</organization>
      <phone>+74952761575 ext 302</phone>
      <email>PutilovskiyMA@materiamedica.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

